TriSalus Life Sciences Inc. Cash Flow-to-Debt Ratio
TriSalus Life Sciences Inc. cash flow-to-debt ratio. TriSalus Life Sciences Inc. (TLSI) has a Cash Flow-to-Debt Ratio of -0.30x as of June 2026, meaning its operating cash flow of $-16.61 Million could theoretically repay 0% of its total liabilities ($55.90 Million) in one year. Check TriSalus Life Sciences Inc. earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of TriSalus Life Sciences Inc. (2021–2025)
Cash flow-to-debt ratio of TriSalus Life Sciences Inc. from 2021 to 2025. Historical debt coverage capacity for TriSalus Life Sciences Inc. across 5 annual periods. Also explore TLSI net assets growth trend to track the company's year-over-year net asset growth rate.
TriSalus Life Sciences Inc. Cash Flow-to-Debt Ratio by Year (2021–2025)
TriSalus Life Sciences Inc. cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for TriSalus Life Sciences Inc.. For the full cash flow conversion analysis, see TriSalus Life Sciences Inc. operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.26x | $-18.01 Million | $69.19 Million | ▲ +68.2% |
| 2024 | -0.82x | $-40.84 Million | $49.87 Million | ▲ +16.3% |
| 2023 | -0.98x | $-50.58 Million | $51.66 Million | ▼ -4.0% |
| 2022 | -0.94x | $-32.31 Million | $34.32 Million | ▲ +71.2% |
| 2021 | -3.27x | $-22.70 Million | $6.93 Million | — |